High levels of antibody in adults three years after vaccination with a reduced antigen content diphtheria-tetanus-acellular pertussis vaccine
- PMID: 15530684
- DOI: 10.1016/j.vaccine.2004.05.030
High levels of antibody in adults three years after vaccination with a reduced antigen content diphtheria-tetanus-acellular pertussis vaccine
Abstract
There is increasing interest in prevention of pertussis in adults by vaccination, but little is known about the duration of the antibody response to pertussis, diphtheria or tetanus in reduced antigen content vaccines formulated for adult use. Follow-up of a clinical trial including 550 adults comparing responses to reduced antigen content diphtheria-tetanus-acellular pertussis (dTpa) vaccine, or a licensed Td vaccine, provided the opportunity to evaluate this. Blood samples were collected at 0, 1, 12, 24 and 36 months following vaccination; of the original cohort of 550, 387 subjects (dTpa group N=310, Td+pa group N=77) were tested at month 36. Following a decrease in antibody levels against all vaccine antigens between one and 24 months following vaccination, levels stabilized during the third year, remaining higher at 36 months than pre-vaccination for all vaccine antigens. In particular, more than 90% of subjects remained seropositive for pertussis toxin and pertactin antibodies at 36 months after vaccination, suggesting ongoing protection against pertussis. Adult-formulated dTpa vaccines could replace Td for routine booster vaccination of older individuals.
Similar articles
-
Combined reduced-antigen-content diphtheria-tetanus-acellular pertussis and polio vaccine (dTpa-IPV) for booster vaccination of adults.Vaccine. 2005 May 25;23(28):3657-67. doi: 10.1016/j.vaccine.2005.02.013. Vaccine. 2005. PMID: 15882526 Clinical Trial.
-
Immunogenicity and reactogenicity of a reduced-antigen-content diphtheria-tetanus-acellular pertussis vaccine as a single-dose booster in Singaporean adults.Singapore Med J. 2006 Apr;47(4):286-90. Singapore Med J. 2006. PMID: 16572239
-
Immunogenicity of reduced antigen content tetanus-diphtheria-acellular pertussis vaccine in adolescents as a sixth consecutive dose of acellular pertussis-containing vaccine.Vaccine. 2007 Jul 20;25(29):5248-52. doi: 10.1016/j.vaccine.2007.05.012. Epub 2007 Jun 4. Vaccine. 2007. PMID: 17583395 Clinical Trial.
-
Acellular pertussis vaccine use in risk groups (adolescents, pregnant women, newborns and health care workers): a review of evidences and recommendations.Vaccine. 2012 Jul 27;30(35):5179-90. doi: 10.1016/j.vaccine.2012.06.005. Epub 2012 Jun 15. Vaccine. 2012. PMID: 22709953 Review.
-
Combined, reduced-antigen content tetanus, diphtheria, and acellular pertussis vaccine (Boostrix): a review of its use as a single-dose booster immunization in individuals aged 10-64 years in the US.BioDrugs. 2009;23(4):253-67. doi: 10.2165/11202770-000000000-00000. BioDrugs. 2009. PMID: 19697967 Review.
Cited by
-
Göttingen Minipigs as a Model to Evaluate Longevity, Functionality, and Memory of Immune Response Induced by Pertussis Vaccines.Front Immunol. 2021 Mar 17;12:613810. doi: 10.3389/fimmu.2021.613810. eCollection 2021. Front Immunol. 2021. PMID: 33815369 Free PMC article.
-
Use of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccines: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2019.MMWR Morb Mortal Wkly Rep. 2020 Jan 24;69(3):77-83. doi: 10.15585/mmwr.mm6903a5. MMWR Morb Mortal Wkly Rep. 2020. PMID: 31971933 Free PMC article.
-
Th1/Th17 polarization persists following whole-cell pertussis vaccination despite repeated acellular boosters.J Clin Invest. 2018 Aug 31;128(9):3853-3865. doi: 10.1172/JCI121309. Epub 2018 Aug 6. J Clin Invest. 2018. PMID: 29920186 Free PMC article.
-
Prevention of Pertussis, Tetanus, and Diphtheria with Vaccines in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP).MMWR Recomm Rep. 2018 Apr 27;67(2):1-44. doi: 10.15585/mmwr.rr6702a1. MMWR Recomm Rep. 2018. PMID: 29702631 Free PMC article.
-
Robust Humoral and Cellular Immune Responses to Pertussis in Adults After a First Acellular Booster Vaccination.Front Immunol. 2018 Apr 4;9:681. doi: 10.3389/fimmu.2018.00681. eCollection 2018. Front Immunol. 2018. PMID: 29670634 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical